We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




BD Diagnostics to Distribute Biotrin's Biomarkers

By HospiMedica staff writers
Posted on 07 Apr 2006
Biotrin (Dublin, Ireland) has announced an agreement with BD Biosciences (San Jose, CA, USA), a segment of Becton, Dickerson and Company, for the distribution of Biotrin's biomarker range of products for the detection of early organ damage. More...
Under the terms of the contract, BD Biosciences has been appointed world-wide distributor of the biomarker range to pharmaceutical companies, contract-research organizations, universities, and research centers.

Using its proprietary Histomics technology, Biotrin identifies and selects biomarkers that allow researchers to determine the exact location and amount of damage an organ has undergone. In addition, the biomarkers help to monitor the progression of damage, which is either caused by disease or the administration of toxic compounds. Biotrin biomarkers have been on the market for several years and the number of products in the range continues to grow.

Biotrin produces tests for human Parovirus B 19, which can cause miscarriage, as well as a number of respiratory virus tests. A number of new kidney damage biomarkers, including a marker that can detect very early kidney damage in diabetic patients, have been discovered using the Histomics approach. These tests are provided to the drug development industry for early detection of nephrotoxic compounds.



Related Links:
Biotrin
BD Biosciences

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Desk Aneroid Sphyg
Diagnostix 750D+
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.